Advanced Renal Cell Carcinoma
Advertisement
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Bempegaldesleukin can initialize effector CD8+ T cells and natural killer cells in the tumor microenvironment.
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Overall survival, TFS, TFS with and without toxicity, and time to all protocol therapy cessation were quantified.
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.